- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Endocrine Society Recommendations on How to Avoid Hypoglycemia in Patients with Diabetes: A Guideline Topline
The Endocrine Society's first update on management of hypoglycemia since 2009 emphasizes the value of new technology and therapeutics in minimizing risk.
The Endocrine Society's updated 2023 clinical practice guideline for managing individuals with diabetes at high risk for hypoglycemia emphasizes the value of continuous glucose monitoring (CGM) and algorithm-driven insulin pumps; and recommends treatment with long-acting insulin analogs rather than NPH human insulin in basal insulin therapy, and short-acting insulin analogs rather than short-acting human insulin in basal-bolus therapy.
The new 10-recommendation guideline is the first update since the 7-recommendation guideline of 2009 and was necessary to incorporate recommendations on advances in technologies and therapeutics, including new formulations of glucagon, and technology-driven inpatient glycemic surveillance and management programs.
Click through the short slideshow here for a Guideline Topline of Management of individuals withdiabetes at high risk for hypoglycemia: an Endocrine Society Clinical Practice Guideline.
